From Lab Bench to Wall Street: UCSF Innovation Behind FDA-Approved Autoimmune Drug
Member Ken Jenkins was quoted in an article by UCSF Innovation Ventures focused on an FDA approved autoimmune drug, Rilzabrutinib, which went from a university invention to a marketable drug.
In the article, Ken is recognized as having played a key role in protecting the intellectual property behind the innovation, as UCSF’s external patent counsel. In discussing the rarity of an academic discovery making it to FDA approval, Ken commented, “It’s really hard to get a drug. As patent counsel, when you see something you worked on, a patent where the drug is approved, it’s very exciting.”
Source